the prognostic value of ighv mutational status with continuous vs time-limited therapy in cll
Published 1 year ago • 586 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
1:56
choosing between continuous and time-limited therapy in patients with high-risk cll
-
1:50
the impact of ighv mutational status in treatment decisions in cll
-
1:14
cll: ighv mutational status
-
2:02
important prognostic factors to evaluate in cll patients in the era of small molecules
-
10:30
leukemia patient story: my 1st symptoms for cll | stephen's story (1/5) | the patient story
-
3:08
recent updates on tp53 mutation in cll
-
4:02
living with chronic lymphocytic leukaemia (cll)
-
0:55
the impact of mrd & genetics on outcomes to time-limited combinations in patients with cll
-
2:08
the differences in outcomes and treatment in cll patients with mutated and unmutated ighv
-
1:17
relevance of prognostic factors in the era of targeted therapies in cll
-
1:57
how genomic testing is used in the prognostication and diagnosis of patients with cll
-
2:31
treatment considerations for ighv-unmutated and mutated cll
-
1:19
the prognostic value of mrd in cll
-
2:38
importance of prognostic factors in the treatment of cll and how to assess them
-
1:07
testing for ighv and tp53 mutations to guide treatment decisions in cll
-
2:32
ifcg for first-line treatment of ighv-mutated cll
-
2:08
prognostic value of high-sensitivity mrd assessment in cll
-
1:59
the role of mrd as a prognostic & predictive biomarker in cll
-
5:03
ighv-mutated vs ighv-unmutated cll | what’s the difference?
-
1:42
the importance of genomic testing in cll prognosis
-
1:04
defining high-risk cll: known and emerging mutations